Aim: We investigated the association of biological sex with the incidence of inter-cycle treatment delays. Patients & methods: This retrospective cohort study included patients receiving first-line chemotherapy. Multivariable logistic regression was used to assess the association between biological sex and a 7-day treatment delay, adjusting for confounders. Results: Among 1904 patients, 1106 (58%) were males and 798 (42%) females. 387 patients (20%) had a treatment delay (54% males, 46% females; p = 0.08). Sex was associated with treatment delays in multivariable analysis (males vs females OR: 0.73, 95% CI 0.57–0.93). Conclusion: The findings are concordant with other studies reporting differences in toxicity profiles of fluorouracil. Further research is required to optimize dosing between males and females.
No takes yet. Share an insight, caveat, or question.
Chambers et al. (2024) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: